Oncology · Advanced Care PlanningTrial Updateclinicalmid-term

Study on Voicing My CHOiCES Tool for Advanced Care Planning in Young Adults with Cancer

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/1/2026, 6:33:48 AM

Assessment confidence: 75% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The study on the Voicing My CHOiCES tool is significant as it addresses a critical gap in advanced care planning for young adults with cancer, potentially enhancing patient communication and reducing anxiety. Pharma companies should keep an eye on the outcomes, as successful implementation could lead to the development of similar supportive care tools that improve patient engagement. Regulatory context from FDA (Ongoing | Cancer Accelerated Approvals) supports the near-term read. Assessment grounded in 21 ranked evidence items (14 high-relevance).

Strategic Assessment

Pharma companies may consider developing or integrating similar tools into their patient support programs to enhance patient engagement and satisfaction. The strongest clinical anchor is Study of Voicing My CHOiCES as Tool for Advanced Care Planning in Young Adults With Cancer (ClinicalTrials.gov), entity match (national cancer institute); patient population match (advanced). In Oncology · Advanced Care Planning, 4 regulatory and 4 competitive items passed relevance filtering for National Cancer Institute.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer); patient population match (advanced). Secondary pressure from Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC. This research addresses a gap in advanced care planning resources for young adults with cancer, potentially influencing future supportive care tools and interventions.

Regulatory Outlook

Regulatory risk is concentrated around Ongoing | Cancer Accelerated Approvals (FDA). Regulatory pathway relevance (approval). The study is unlikely to have immediate regulatory implications, but positive outcomes could influence future guidelines for patient support tools.

Key Opportunities

If the tool proves effective, it could lead to increased patient satisfaction and loyalty, impacting market share for companies that integrate such tools into their offerings.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.
Upside for National Cancer Institute may improve if A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor the outcomes of the study, particularly the impact on anxiety and communication, as well as any subsequent adoption of the tool in clinical practice.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Study of Voicing My CHOiCES as Tool for Advanced Care Planning in Young Adults With Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (advanced)
FDA document
View source
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (advanced)
FDA document
View source
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
ClinicalTrials.govhigh relevance
Entity match (national cancer institute); Patient population match (advanced)
FDA document
View source
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer); Patient population match (advanced)
Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC
Humanexa Signalshigh relevance
Patient population match (advanced)
Deep Learning Model Enhances Prognostic Prediction in Stage III Colon Cancer
Humanexa Signalsmedium relevance
Moderate corpus alignment
Bristol-Myers Squibb Evaluates Pumitamig vs Pembrolizumab in NSCLC Trial
Humanexa Signalsmedium relevance
Moderate corpus alignment

Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Risk Factors, Cancer Types and Prognostic Significance of Second Primary Cancer After Early-, Intermediate- and Late-Onset Colorectal Cancer: A Retrospective Study in Chinese High-Volume Cancer Center
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
RBM15B-mediated m6A modification of FOXM1 activates the AURKA/TPX2 axis to promote epithelial-mesenchymal transition-driven endometrial cancer progression.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant Erwinia in pediatrics and adolescents/young adults with acute lymphoblastic leuke
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

National Cancer Institute
young adults with cancer

Commercial impact

medium

If the tool proves effective, it could lead to increased patient satisfaction and loyalty, impacting market share for companies that integrate such tools into their offerings.

Regulatory impact

low

The study is unlikely to have immediate regulatory implications, but positive outcomes could influence future guidelines for patient support tools.

What to watch

Monitor the outcomes of the study, particularly the impact on anxiety and communication, as well as any subsequent adoption of the tool in clinical practice.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.